{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:53:43Z","timestamp":1785430423755,"version":"3.56.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We explored the efficacy of the combination of ibrutinib + venetoclax in patients with relapsed and\/or refractory (R\/R) chronic lymphocytic leukemia (CLL). This phase II study enrolled 80 patients between July 2016 and September 2018. Patients received ibrutinib for the first 3 cycles, followed by ibrutinib + venetoclax for 24 cycles. Of the 79 treated patients, the median age was 61 years (IQR, 56\u201369); 65 (65\/76, 86%) had unmutated IGHV and 29 (37%) had either del(17p) or a TP53 mutation. The median number of prior treatments was 1 (range, 1\u20133). The primary endpoint, best complete remission (CR) and CR with incomplete count recovery (CRi), was 67%, with a bone marrow undetectable measurable residual disease [10\u22124 sensitivity (U-MRD4)] rate of 61%. At 95.5 months of median follow-up, the estimated 7-year progression-free survival rate was 63.3%. Grade \u22653 neutropenia and thrombocytopenia occurred in 38% and 13% of patients, respectively. The 24-cycle ibrutinib + venetoclax combination led to high rates of CR\/CRi and bone marrow U-MRD4 in patients with R\/R CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The 24-cycle ibrutinib + venetoclax combination led to high rates of CR\/CRi and bone marrow U-MRD4 in patients with R\/R CLL. Responses were durable, including in patients with high-risk genomics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0345","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:45:48Z","timestamp":1770929148000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ibrutinib with Venetoclax in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: A Phase II Study"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-397X","authenticated-orcid":false,"given":"Mahesh","family":"Swaminathan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-4193","authenticated-orcid":false,"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a8bt934","id-type":"ROR","asserted-by":"publisher"}],"name":"Peter MacCallum Cancer Center 2 Department of Clinical Hematology, , Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-3613","authenticated-orcid":false,"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9394-8663","authenticated-orcid":false,"given":"Vanthana","family":"Bharathi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Hematopathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Hematopathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Hematopathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-2813","authenticated-orcid":false,"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 Department of Radiology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-5145","authenticated-orcid":false,"given":"Hyunsoo","family":"Hwang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-0966","authenticated-orcid":false,"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0922-0726","authenticated-orcid":false,"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-1864","authenticated-orcid":false,"given":"Xun","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5171-9039","authenticated-orcid":false,"given":"Nichole","family":"Cruz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4612-0991","authenticated-orcid":false,"given":"Ana","family":"Ayala","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9542-1558","authenticated-orcid":false,"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9311-2164","authenticated-orcid":false,"given":"William","family":"Plunkett","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 6 Department of Experimental Therapeutics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-8436","authenticated-orcid":false,"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 7 Department of Hematopoietic Biology and Malignancy, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-6450","authenticated-orcid":false,"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 6 Department of Experimental Therapeutics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026050503063528100_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia","volume":"404","author":"Jain","year":"2024","journal-title":"Lancet"},{"key":"2026050503063528100_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"2026050503063528100_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"2026050503063528100_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib7","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026050503063528100_bib8","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.bneo.2024.100034","article-title":"Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice","volume":"1","author":"Timofeeva","year":"2024","journal-title":"Blood Neoplasia"},{"key":"2026050503063528100_bib9","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"2026050503063528100_bib10","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/leu.2017.129","article-title":"Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition","volume":"31","author":"Slinger","year":"2017","journal-title":"Leukemia"},{"key":"2026050503063528100_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026050503063528100_bib12","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib13","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"2026050503063528100_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026050503063528100_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","volume":"390","author":"Munir","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050503063528100_bib17","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026050503063528100_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2022-166700","article-title":"MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the Blood Cancer UK TAP CLARITY study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"key":"2026050503063528100_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026050503063528100_bib20","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION\/HO141 trial","volume":"9","author":"Niemann","year":"2025","journal-title":"Blood Adv"},{"key":"2026050503063528100_bib21","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood.2024026879","article-title":"Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: the SAKK 34\/17 trial","volume":"145","author":"Condoluci","year":"2025","journal-title":"Blood"},{"key":"2026050503063528100_bib22","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026050503063528100_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"2026050503063528100_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050503063528100_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/Small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 CAPTIVATE study","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"key":"2026050503063528100_bib26","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.3390\/ijms24065802","article-title":"Landscape of BCL2 resistance mutations in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukemia treated with venetoclax","volume":"24","author":"Kotmayer","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050503063528100_bib27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"key":"2026050503063528100_bib28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/OP.23.00770","article-title":"Current approaches and novel agents in the treatment of chronic lymphocytic leukemia","volume":"20","author":"Cheson","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026050503063528100_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/hematology.2022000344","article-title":"Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax","volume":"2022","author":"Scarf\u00f2","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026050503063528100_bib30","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2024.42.16_suppl.7009","article-title":"Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"42","author":"Wierda","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050503063528100_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hon.3163_156","article-title":"Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)","volume":"41","author":"Kater","year":"2023","journal-title":"Hematological Oncol"},{"key":"2026050503063528100_bib32","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv Ther"},{"key":"2026050503063528100_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/10428194.2024.2331631","article-title":"Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study","volume":"65","author":"Huntington","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"2026050503063528100_bib34","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"2026050503063528100_bib35","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1","article-title":"Optimal three-stage designs for phase II cancer clinical trials","volume":"16","author":"Chen","year":"1997","journal-title":"Stat Med"},{"key":"2026050503063528100_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","article-title":"Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes","volume":"14","author":"Thall","year":"1995","journal-title":"Stat Med"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0345\/3737707\/bcd-25-0345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0345\/3765937\/bcd-25-0345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/431\/3783098\/bcd-25-0345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/431\/3783098\/bcd-25-0345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:06:46Z","timestamp":1777964806000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/3\/431\/784442\/Ibrutinib-with-Venetoclax-in-Patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0345","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8541882","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.32696892","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696886","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696889","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}